Four reasons to buy Azure

With the company’s medium-term opportunities set to create value, the recent share price weakness represents a buying opportunity for patient investors.

Shares in Azure Healthcare (AZV) have fallen 30 per cent over the past few months to today’s close of 24.5 cents, as shown in the graph below.

The recent share price weakness is at least partly due to aggressive on market selling from a prior top 10 shareholder.  

We maintain our positive view on the company, with the stock trading at a large discount to our 44 cent valuation.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles